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Background: Antimicrobial catheters have been utilized to reduce risk of catheter colonization and infection. We
aimed to determine if there is a greater than expected risk of microorganism-specific colonization associated with
the use of antimicrobial central venous catheters (CVCs).
Methods: We performed a meta-analysis of 21 randomized, controlled trials comparing the incidence of specific
bacterial and fungal species colonizing antimicrobial CVCs and standard CVCs in hospitalized patients.
Results: The proportion of all colonized minocycline-rifampin CVCs found to harbor Candida species was greater
than the proportion of all colonized standard CVCs found to have Candida. In comparison, the proportion of
colonized chlorhexidine-silver sulfadiazine CVCs specifically colonized with Acinetobacter species or diphtheroids
was less than the proportion of similarly colonized standard CVCs. No such differences were found with CVCs
colonized with staphylococci.
Conclusion: Commercially-available antimicrobial CVCs in clinical use may become colonized with distinct
microbial flora probably related to their antimicrobial spectrum of activity. Some of these antimicrobial CVCs may
therefore have limited additional benefit or more obvious advantages compared to standard CVCs for specific
microbial pathogens. The choice of an antimicrobial CVC may be influenced by a number of clinical factors,
including a previous history of colonization or infection with Acinetobacter, diphtheroids, or Candida species.
Keywords: Central venous catheter, Catheter colonization, Catheter-related bloodstream infection,
Central line-associated bloodstream infection, Bacteremia, Antimicrobial catheterIntroduction
Central venous catheters (CVCs) have become essential
in the management of critically ill patients, as well as
other patient populations requiring acute or long-term
medical care. Intravascular catheters can become colo-
nized by microbial pathogens following an extraluminal
or intraluminal route of endemic infection emanating
from the insertion site and catheter connector/hub,
respectively [1]. Meta-analyses have been published
demonstrating a reduced risk of CVC colonization and
CVC-related bloodstream infection with some of the* Correspondence: lmermel@lifespan.org
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reproduction in any medium, provided the orcurrently marketed antimicrobial CVCs [2-4]. However,
there are no publications that have systematically
reviewed prospective, randomized clinical trials compar-
ing antimicrobial CVCs with non-antimicrobial CVCs to
determine if there are differences in the incidence of
species-specific CVC colonization that might suggest a
lack of efficacy for specific pathogens. We hypothesized
that some currently marketed antimicrobial CVCs may
lack activity against specific microbial pathogens, and as
such, may select for colonization and eventual blood-
stream infection caused by such pathogens. We analyzed
available data to determine if there is a proven benefit at
the species-specific level for use of antimicrobial CVCs
and to determine if some of these CVCs may have any
vulnerability in their antimicrobial spectra. We studied
CVC colonization rather than CVC-related bloodstreaml Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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microbial colonization prior to the development of
CVC-related bloodstream infection. Additionally, most
studies have shown a 2 to 10-fold increase in episodes of
CVC colonization compared to CVC-related blood-
stream infection [2]. Thus, the greatest likelihood of
uncovering any potential gaps in the spectrum of activity
of antimicrobial CVCs would best be done by assessing
CVC colonization.
Materials and methods
We reviewed prospective, randomized clinical trials com-
paring antimicrobial CVCs to non-antimicrobial control
CVCs. Inclusion criteria were as previously described [2].
In brief, we performed a search in Cochrane, MEDLINE,
and EMBASE databases of randomized controlled trials
from 1995 to current with the following strings: “centrall
l
Figure 1 *RCT: Randomized controlled trial.venous catheter”, “colonization”, “catheter colonization”,
“bloodstream infection”, “bacteremia”, “chlorhexidine”,
“benzalkonium chloride”, “rifampicin”, “minocycline”,
“silver”, and “miconazole”. We chose to search from 1995
onwards as this was when the first study was published in
those included in our first meta-analysis [2]. Catheter
colonization was defined as at least 15 CFUs of microbial
growth by semi-quantitative culture [5], or at least 1000
CFUs after quantitative vortex culture [6], or at least 100
CFUs after vortexing and sonication [6]. All statistical ana-
lyses were performed with MetAnalysis 1.0 software. Gart
odds ratios (ORs) with 95% CIs were calculated for each
study that met entry criteria. For each antimicrobial CVC,
we analyzed the number of antimicrobial CVCs colonized
with a specific microorganism or related group of microor-
ganisms as a fraction of all colonized antimicrobial CVCs
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the same way.
Microorganism colonized control CVCs
All colonized control CVCs
vs:
Microorganism colonized test CVCs
All colonized test CVCs
The rate of CVC colonization for each microorganism
was analyzed separately and various pooled odds ratios
(ORs) were calculated by both the Gart fixed-effects models
(FEMs) and the DerSimonian-Laird random-effects models
(REMs). The Cochran Q statistics and I2 test were used to
assess heterogeneity. I2 values of 0% indicates no observed
heterogeneity, whereas larger values indicated increasing
heterogeneity. Results of the Gart FEM are quoted unless
substantial heterogeneity was found, in which case the
results of the DerSimonian-Laird REM are stated. We only
included trials meeting our previously published criteria.
Additionally, we only included those studies in which
species-specific rates of colonization were delineated orTable 1 Baseline characteristics of the studies used in the me
Study CVC type Study
double-blinded?
Goldschmidt et al. 1995 [10] Silver vs standard –
Bach et al. 1996 [11] CHSS vs. standard –
Ciresi et al. 1996 [12] CHSS vs. standard –
van Heerden et al. 1996 [13] CHSS vs. standard –
Maki et al. 1997 [5] CHSS vs. standard yes
Heard et al. 1998 [7] CHSS vs. standard –
Bach et al 1999 [14] Silver vs standard –
Collin et al. 1999 [15] CHSS vs. standard –
Hannan et al. 1999 [16] CHSS vs. standard no
Marik et al. 1999 [17] CHSS vs. standard
and MR vs. standard
no
Sheng et al. 2000 [18] CHSS vs. standard yes
Jaeger et al. 2001 [19] Benzalkonium chloride
vs. standard
no
Corral et al. 2003 [20] Silver vs standard no
Brun-Buisson et al. 2004 [21] CHSS vs standard yes
Leon et al. 2004 [22] MR vs. standard no
Yucel et al. 2004 [23] Miconazole-rifampicin
vs. standard
no
Dunser et al. 2005 [24] Silver vs standard no
Rupp et al. 2005 [8] CHSS vs. standard yes
Osma et al. 2006 [25] CHSS vs. standard –
Kalfon et al. 2007 [26] Silver vs. standard no
Raad et al.1997 [9] MR vs. standard no
CVC (central venous catheter); CHSS (chlorhexidine - silver sulfadiazine); MR (minocythose studies in which we were able to contact the authors
directly to obtain species-specific colonization rates for
antimicrobial and non-antimicrobial CVC groups. Our final
analysis included an assessment for rates of CVC
colonization for specific microbial species if available. If
authors used the terms ‘coliforms’ or ‘diphtheroids’, we ana-
lyzed colonization rates but we did not combine these
results with species-specific data. If the information regard-
ing CVC colonization was insufficient, we attempted to
contact the study corresponding author. We requested add-
itional information from eleven authors; three authors
responded before the final analysis was completed. As
such, these latter studies [7-9] were included in the
final analysis.
Results
Twenty-one randomized, controlled trials met our inclu-
sion criteria [5,7-26] (Figure 1; Tables 1 and 2). Combining
all antimicrobial CVCs, there was no significant difference
in the proportion of colonized antimicrobial CVCs that
were colonized by Staphylococcus aureus or coagulase-













no yes 12.4% no
no no – no
yes yes 5.4% no
no no 11.5% no
yes yes 8.8% no
yes yes 15.6% no
yes no 13% no
yes yes 2.1% no
no yes – no
no no 5.8% no
no yes – no
no no – no
yes yes 19.8% no
yes yes 8.6% no
no no 21.1% yes
no no 29.4% no
no no – no
yes no 9.4% yes
no no 0% yes
no yes 19.2% no
no yes 10.7% no
cline-rifampin); “-” not reported.
Table 2 Rates of colonization of the study and control catheters
Study Mean catheter dwell time






n Rate per 1000 days
Goldschmidt et al. 1995 [10] 13.3 vs 12.7 120 vs 113 54 (45.1%) vs 50 (44.2%) 33.8 vs 34.8
Bach et al. 1996 [11] 7.8 vs 7.8 116 vs 117 21 (18.1%) vs 36 (30.8%) 23.2 vs 39.4
Ciresi et al. 1996 [12] 12.9 vs 11.5 124 vs 127 10 (10.9%) vs 12 (12.1%) 6.3 vs 8.2
van Heerden et al. 1996 [13] 6.6 vs .6.8 28 vs 26 4 (14.3%) vs 10 (38.5%) 21.6 vs 56.6
Maki et al. 1997 [5] 6 vs 6 208 vs 195 28 (13.5%) vs 47 (24.1%) 22.4 vs 40.2
Heard et al. 1998 [7] 8.5 vs 9.0 151 vs 157 60 (39.7%) vs 81 (51.6%) 46.7 vs 57.3
Bach et al 1999 [14] 4.5 vs 2.3 34 vs 33 9 (26.5%) vs 7 (21.2%) 58.8 vs 52.2
Collin et al. 1999 [15] 9.0 vs 7.3 98 vs 139 2 (2.0%) vs 25 (18%) 2.3 vs 24.6
Hannan et al. 1999 [16] 7.5 vs 7.6 174 vs 177 47 (27.2%) vs 71 (40.2%) 36.0 vs 52.8
Marik et al. 1999 [17] 6 vs 6 vs 6 36 vs 38 vs 39 7 (19.4%) vs 4 (10.5%) vs 11 (28.2%) 32.4 vs 17.5 vs 47.0
Sheng et al. 2000 [18] 9.1 vs 8.2 113 vs 122 9 (7.1%) vs 25 (20.5%) 8.8 vs 25
Jaeger et al. 2001 [19] 14.8 vs 19.3 25 vs 25 4 (16.0%) vs 4 (16.0%) 10.8 vs 8.3
Corral et al. 2003 [20] 12 vs14 103 vs 103 29 (28.2%) vs 41 (39.8%) 23.5 vs 27.7
Brun-Buisson et al. 2004 [21] 10.5 vs 12.0 188 vs 175 7 (3.7%) vs 23 (13.1%) 3.6 vs 11.0
Leon et al. 2004 [22] 10.3 vs 10.4 187 vs 180 20 (10.7%) vs 45 (25.0%) 10.4 vs 24.0
Yucel et al. 2004 [23] 7.5 vs 6.7 118 vs 105 6 (5.1%) vs 38 (36.2%) 6.8 vs 54.0
Dunser et al. 2005 [24] 9.3 vs 9.7 vs 10.7 160 vs 165 vs 160 27 (16.9%) vs 12 (7.3%) vs 19 (11.9%) 18.1 vs 7.5 vs 11.9
Rupp et al. 2005 [8] 6.9 vs. 6.7 384 vs 393 32 (9.3%) vs 59 (16.3%) 12.1 vs 22.4
Osma et al. 2006 [25] 11.7 vs 8.9 64 vs 69 14 (21.9%) vs 14 (20.3%) 18.7 vs 22.8
Kalfon et al. 2007 [26] 13.1 vs 12.9 320 vs 297 47 (14.7%) vs 36 (12.1%) 11.2 vs 9.4
Raad et al. 1997 [9] 6 vs 6 130 vs 136 11 (8·5%) vs 36 (26·5%) 14.1 vs 44.1
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Similarly, the proportion of S. aureus or coagulase-
negative staphylococci colonized chlorhexidine-silver sul-
fadiazine, minocycline-rifampin, or silver antimicrobial
CVCs was similar to the total proportion of colonized
control CVCs. The proportion of miconazole-rifampin
CVCs colonized with coagulase-negative staphylococci
was less than the standard CVCs. However, this reflected
the results of a single study [23].
The findings also demonstrated that there was no sig-
nificant difference in the proportion of antimicrobial
CVCs specifically colonized with Acinetobacter species
compared to the proportion of Acinetobacter colonized
control CVCs (Figure 4). Among those antimicrobial
CVCs, the chlorhexidine-silver sulfadiazine CVCs colo-
nized with Acinetobacter species were significantly less
frequent, compared to corresponding colonized control
CVCs (OR 0.16 [95%CI 0.04-0.64]). However, publica-
tion bias was detected (P=0.01).
The proportion of antimicrobial CVCs that were colo-
nized with diphtheroids was less than that of colonized
control CVCs (OR 0.45 [95%CI 0.25-0.79]). The proportion
of colonized chlorhexidine-silver sulfadiazine CVCs that
were colonized by diphtheroids was less than that of colo-
nized standard control CVCs (OR 0.43 [95%CI 0.23-0.82]).Combining all antimicrobial CVCs, the proportion of
colonized CVCs that were colonized by coliforms was
greater than that of standard CVCs (OR 2.38 [95%CI 1.10-
5.15]). The proportion of coliform-colonized silver CVCs
and minocycline-rifampin CVCs was greater than that of
standard control CVCs (Figure 5). However, these findings
each represented only a single clinical trial [20,22].
Combining all antimicrobial CVCs, there was no signifi-
cant difference in the proportion of colonized antimicrobial
CVCs colonized with Candida species compared to colo-
nized standard CVCs (Figure 6). However, the proportion
of colonized minocycline-rifampin CVCs colonized with
Candida species was greater than that of colonized stand-
ard CVCs (OR 13.6 [95%CI 4.2-43.4]).
Discussion
Antimicrobial-coated CVCs were developed in an effort to
mitigate risk of serious CVC-related infections. Meta-
analyses have shown that chlorhexidine-silver sulfadiazine
CVCs, and particularly minocycline-rifampin CVCs, reduce
the risk of CRBSI in prospective, randomized trials [2-4].
We compared data regarding colonization of antimicrobial
and standard CVCs with known microorganisms that can
cause CRBSI with an aim to investigate any potential vul-
nerability in the spectrum of antimicrobial activity. We
Brun-Buisson et al. 2004 [21] 8/23* 4/7
Ciresi et al. 1996 [12] 4/12 3/10
Collin et al. 1999 [15] 9/25 1/2
Dunser et al. 2005 [24] 14/19 7/12
Hannan et al. 1999 [16] 39/71 24/47
Maki et al. 1997 [5] 34/47 24/28
Marik et al. 1999 [17] 6/11 4/7
Osma et al. 2006 [25] 4/14 2/14
Rupp et al. 2005 [8] 42/59 22/32
Sheng et al. 2000 [18] 9/25 5/9
van Heerden et al. 1996 [13] 7/10 4/4
Heard et al. 1998 [7] 42/81 33/60




Corral et al. 2003 [20] 21/29 7/15
Dunser et al. 2005 [24] 14/19 20/27
Goldschmidt et al. 1995 [10] 47/50 50/54
Kalfon et al. 2007 [26] 21/36 32/47
Bach et al 1999 [14] 4/7 7/9




Leon et al. 2004 [22] 40/45 5/20
Marik et al. 1999 [17] 6/11 3/4                       
Raad et al. 1997 [9] 19/36 2/11
Total (REM) 65/92 10/35
Test for heterogeneity         Q=8.33, p=.016; I2=88% OR 0.24 (0.03-1.67)
Benzalkonium Chloride
Jaeger et al. 2001 [19] 4/4 4/4
Miconazole-Rifampin
Yucel et al. 2004 [23] 34/41 2/7
Total CVC (REM) 456/711 286/451
Test for heterogeneity  Q=38.42, p=005; I2=53.2% OR 0.84 (0.55-1.28)
1/64        1/16          1/4            1              4             16            64
Favors test catheter Favors control catheter
Test for heterogeneity       Q=8.99, p=1.0;  I2=0%
Test for heterogeneity     Q=4.26, p=1.0; I2=29.5%
OR (95% CI)ORtest cathetercontrol catheterStudy           
#
154/253
Figure 2 Horizontal lines represent 95% confidence intervals (95% CI) of CVC colonization with coagulase-negative staphylococci in
different trials. They express the likelihood of test vs. control catheter colonization in relation to the vertical line that represents the null
hypothesis of no difference between test and control catheters. For every type of catheter tested, the data from available trials was pooled and
graphed as Gart fixed-effects model (FEM). If substantial heterogeneity was present, DerSimonian-Laird random-effects model (REM) results were
used instead. *Coagulase-negative staphylococci colonized control CVCs/All colonized control CVCs. #Coagulase-negative staphylococci colonized
test CVCs/All colonized test CVCs.
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have unique activity in reducing risk of colonization by
Acinetobacter species and diphtheroids, but the former find-
ing needs to be confirmed since we detected publication bias.
Single study findings suggest that the miconazole-rifampin
CVC may reduce the risk of colonization by coagulase-negative staphylococci, while the silver CVC and
minocycline-rifampin CVC may be more vulnerable to
coliform colonization, but these observations need to
be confirmed by future studies. We identified a significant
increase in the proportion of Candida species colonization
among colonized minocycline-rifampin CVCs. Published
Brun-Buisson et al. 2004 [21] 2/23* 3/7
Ciresi et al. 1996 [12] 0/12 2/10
Collin et al. 1999 [15] 4/25 0/2
Dunser et al. 2005 [24] 1/19 1/12
Hannan et al. 1999 [16] 9/71 7/47
Maki et al. 1997 [5] 1/47 1/28
Marik et al. 1999 [17] 2/11 1/7
Osma et al. 2006 [25] 1/14 2/14
Rupp et al. 2005 [8] 10/59 4/32
Bach et al. 1996 [11] 4/36 0/21
Total (FEM) 34/317 21/180                              
Test for heterogeneity Q=6.96, p=.64; I2=0%
Chlorhexidine-Silver Sulfadiazine
Silver
Dunser et al. 2005 [24] 1/19 1/27
Goldschmidt et al. 1995 [10] 1/50     3/54
Kalfon et al. 2007 [26] 1/36 5/47
Total (FEM) 3/105 9/128
Test for heterogeneity Q=0.98, p=.61; I2=0%
Minocycline-Rifampin
Marik et al. 1999 [17] 2/11 1/4                       
Raad et al. 1997 [9] 1/36 0/11
Total (FEM) 3/47 1/15
Test for heterogeneity Q=0.05, p=.82; I2=0% OR 0.95(0.09-10.2)
Total CVC (FEM) 45/510 32/330
Test for heterogeneity Q=8.33, p=0.91; I2=0% OR 1.32 (0.79-2.19)
1/64 1/16 1/4 1 4 16 64




Yucel et al. 2004 [23] 5/41 1/7
OR (95% CI)OR
OR
test cathetercontrol catheterStudy           
#
Figure 3 Horizontal lines represent 95% confidence intervals (95% CI) of CVC colonization with S. aureus in different trials. They express
the likelihood of test vs. control catheter colonization in relation to the vertical line that represents the null hypothesis of no difference between
test and control catheters. For every type of catheter tested, the data from available trials was pooled and graphed as Gart fixed-effects model
(FEM). If substantial heterogeneity was present, DerSimonian-Laird random-effects model (REM) results were used instead. *S. aureus colonized
control CVCs/All colonized control CVCs. #S. aureus colonized test CVCs/All colonized test CVCs.
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related bloodstream infections due to Candida species but
these studies are underpowered to detect such a difference.
Our findings regarding minocycline-rifampin CVC col-
onization with Candida species, as well as coliforms, sup-
port the observations of other investigators [22,27-29].
Some investigators found significantly less microbial adhe-
rence of Enterobacter aerogenes, Escherichia coli, Klebsiella
pneumoniae, and C. albicans to chlorhexidine-silver sulfa-
diazine CVCs compared to non-antimicrobial CVCs but no
such difference when minocycline-rifampin CVCs or silver
CVCs were tested [28]. Additionally, they found increasedmicrobial adherence of C. albicans to minocycline-rifampin
CVCs compared to control CVCs in an in vitro model.
Our study has important limitations. We looked at
CVC colonization rather than CVC-related bloodstream
infection. However, as previously stated, for endemic
intravascular CVC infections, CVC colonization is a pre-
requisite for bloodstream infection. As such, we feel that
our findings have clinical relevance. We were unable to
assess differences in CVC colonization based on the ana-
tomic site of CVC insertion as this information was un-
available in the majority of the studies included in our




1/64 1/16 1/4 1 4 16 64
Favors test catheter Favors control catheter
Collin et al. 1999 [11] 2/25* 0/2
Dunser et al. 2005 [24] 1/19 0/12
Osma et al. 2006 [25] 3/14 0/14
van Heerden et al. 1996 [13] 3/10 0/4
Heard et al. 1998 [7] 2/81 0/60
Total (FEM) 11/149 0/92
Test for heterogeneity    Q=1.65  p=1.0;  I2=0%
Dunser et al. 2005 [24] 1/19 3/27
Kalfon et al. 2007 [26] 1/36 1/47
Total (FEM) 2/55 4/74 
Test for heterogeneity    Q=.29,   p=.59;  I2=0%
Silver
OR 0.38 (0.14-1.05)
Total CVC (FEM) 16/245 4/173
Test for heterogeneity  Q=3.37 (df=7),  p=.085;  I2=0%
OR 1.45 (0.28-7.66)
Miconazole-Rifampin
Yucel et al. 2004 [23] 3/41 0/7
OR (95% CI)ORtest cathetercontrol catheterStudy           
#
Figure 4 Horizontal lines represent 95% confidence intervals (95% CI) of CVC colonization with Acinetobacter in different trials. They
express the likelihood of test vs. control catheter colonization in relation to the vertical line that represents the null hypothesis of no difference
between test and control catheters. For every type of catheter tested, the data from available trials was pooled and graphed as Gart fixed-effects
model (FEM). If substantial heterogeneity was present, DerSimonian-Laird random-effects model (REM) results were used instead. *Acinetobacter
colonized control CVCs/All colonized control CVCs. #Acinetobacter colonized test CVCs/All colonized test CVCs.
Brun-Buisson et al. 2004 [21] 7/23* 0/7
Hannan et al. 1999 [16] 5/71 4/47
Total (FEM) 12/94 4/54
Test for heterogeneity  Q=1.66, p=1.0;    I2=0%
Chlorhexidine-Silver Sulfadiazine
Silver
Corral et al. 2003 [20] 3/29 7/15
OR 0.67 (0.22-2.07)
Minocycline-Rifampin
Leon et al. 2004 [22] 3/45 6/20
Total CVC (FEM) 18/168 17/89
Test for heterogeneity  Q=7.34, p=.06;  I2=72.7% OR 2.38 (1.10-5.15)
OR
1/64 1/16 1/4  1 4 16 64
Favors test catheter Favors control catheter
OR (95% CI)ORtest cathetercontrol catheterStudy           
#
Figure 5 Horizontal lines represent 95% confidence intervals (95% CI) of CVC colonization with coliform bacteria in different trials.
They express the likelihood of test vs. control catheter colonization in relation to the vertical line that represents the null hypothesis of no
difference between test and control catheters. For every type of catheter tested, the data from available trials was pooled and graphed as Gart
fixed-effects model (FEM). If substantial heterogeneity was present, DerSimonian-Laird random-effects model (REM) results were used instead.
*Coliforms colonized control CVCs/All colonized control CVCs. #Coliforms colonized test CVCs/All colonized test CVCs.
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Brun-Buisson et al. 2004 [21] 2/23* 0/7
Ciresi et al. 1996 [12] 4/12 4/10
Collin et al. 1999 [15] 2/25 0/2
Maki et al. 1997 [5] 8/47 1/28
Marik et al. 1999 [17] 1/11 1/7
Osma et al. 2006 [25] 2/14 1/14
Rupp et al. 2005 [8] 2/59 4/32
Sheng et al. 2000 [18] 7/25 1/9
Heard et al. 1998 [7] 2/81 0/60
Total (FEM) 30/297 12/169
Test for heterogeneity  Q=6.82, p=1.0;  I2=0%
Chlorhexidine-Silver Sulfadiazine
Silver
Corral et al. 2003 [20] 0/29 2/15
Kalfon et al. 2007 [26] 1/36 0/47
Total (FEM) 1/65 2/62




Leon et al. 2004 [22] 2/45 9/20
Marik et al. 1999 [17] 1/11 0/4
Raad et al. 1997 [9] 1/36 3/11
Total (FEM) 4/92 12/35
Test for heterogeneity  Q=2.37, p=.31; I2=57.8%
OR 13.56 (4.24-43.37)
Miconazole-Rifampin
Yucel et al. 2004 [23] 2/41 0/7
Total CVC (FEM) 37/495 26/273
Test for heterogeneity  Q=23.27, p=0.056; I2=44% OR 1.53 (.86-2.72)
OR
1/64 1/16 1/4 1 4 16 64
Favors test catheter Favors control catheter
OR (95% CI)ORtest cathetercontrol catheterStudy
#
Figure 6 Horizontal lines represent 95% confidence intervals (95% CI) of CVC colonization with Candida species in different trials. They
express the likelihood of test vs. control catheter colonization in relation to the vertical line that represents the null hypothesis of no difference
between test and control catheters. For every type of catheter tested, the data from available trials was pooled and graphed as Gart fixed-effects
model (FEM). If substantial heterogeneity was present, DerSimonian-Laird random-effects model (REM) results were used instead. *Candida species
colonized control CVCs/All colonized control CVCs. #Candida species colonized test CVCs/All colonized test CVCs.
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bial CVCs were performed.
Prospective studies and the ensuing meta-analyses
have demonstrated the attributes of antimicrobial CVCs.
However, we were interested in further understanding
potential unintended consequences of widespread use of
such devices. The data presented herein suggest that
some antimicrobial CVCs may not reduce risk of CVC
infections due to Candida or coliforms compared to un-
coated CVCs despite showing overall benefit in clinical
trials. As such, clinicians should weigh potential risks
and benefits when contemplating use of specific anti-
microbial CVCs in patients with prior colonization orinfection due to these pathogens or when the patients
are located in clinical areas where these microorganisms
are endemic. Novel CVCs combining components of
previously studied catheters have been demonstrated to
have broader antimicrobial coverage and may well be
less prone to colonization with select microorganisms as
demonstrated in our investigation [30].Competing interests
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